NOVEN TO PRESENT AT UPCOMING INVESTOR CONFERENCES |
BackMiami, FL, September
5, 2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that it is scheduled to present at two upcoming investor conferences.
Robert Strauss, Noven’s President, CEO & Chairman, will present
at the Thomas Weisel Partners Healthcare Conference in Boston on Friday,
September 7th at 10:55 a.m. ET, and at the Bear Stearns 20th Annual
Healthcare Conference in New York City on Tuesday, September 11th at
8:00 a.m. ET. The public is invited to listen to the presentations
live via webcast at www.noven.com, and a replay will be available for
at least two weeks at the same site.
About
Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, has established
itself as a leading developer of advanced transdermal drug delivery technologies
and prescription transdermal products. Its commercialized transdermal
products include Vivelle-Dot® (estradiol transdermal system), the
most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate
transdermal system), the first and only patch approved for the treatment
of ADHD.
With the acquisition of JDS Pharmaceuticals in August 2007, Noven has
become a broader-based specialty pharmaceutical company with the infrastructure,
products and category expertise to market and sell products itself, and
with a substantially enhanced late-stage product pipeline.
See www.noven.com
for additional information.
Contact:
|
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.